作者
Pierre Van Damme, Ilse De Coster, Ananda S Bandyopadhyay, Hilde Revets, Kanchanamala Withanage, Philippe De Smedt, Leen Suykens, M Steven Oberste, William C Weldon, Sue Ann Costa-Clemens, Ralf Clemens, John Modlin, Amy J Weiner, Andrew J Macadam, Raul Andino, Olen M Kew, Jennifer L Konopka-Anstadt, Cara C Burns, John Konz, Rahnuma Wahid, Christopher Gast
发表日期
2019/7/13
期刊
The Lancet
卷号
394
期号
10193
页码范围
148-158
出版商
Elsevier
简介
Background
Use of oral live-attenuated polio vaccines (OPV), and injected inactivated polio vaccines (IPV) has almost achieved global eradication of wild polio viruses. To address the goals of achieving and maintaining global eradication and minimising the risk of outbreaks of vaccine-derived polioviruses, we tested novel monovalent oral type-2 poliovirus (OPV2) vaccine candidates that are genetically more stable than existing OPVs, with a lower risk of reversion to neurovirulence. Our study represents the first in-human testing of these two novel OPV2 candidates. We aimed to evaluate the safety and immunogenicity of these vaccines, the presence and extent of faecal shedding, and the neurovirulence of shed virus.
Methods
In this double-blind, single-centre phase 1 trial, we isolated participants in a purpose-built containment facility at the University of Antwerp Hospital (Antwerp, Belgium), to minimise the risk of …
学术搜索中的文章
P Van Damme, I De Coster, AS Bandyopadhyay… - The Lancet, 2019